Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BST06 in advanced hepatocellular carcinoma
NCT06645314Phase 1Not yet recruiting
- Sponsor
- Biosyngen
- Start
- Nov 2024
- Primary completion
- Aug 2026
- Modality
- Cell Therapies
01
Overview
Phase 1, open-label trial of BST-06 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Biosyngen. Primary endpoints: Dose-Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
BST-06
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06645314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06645314.